Biological shares announced that the operating income in the third quarter was 498 million yuan, an increase of 3.02% over the same period last year. The net profit belonging to shareholders of listed companies was 161 million yuan, up 41.83% from the same period last year.
According to the third quarterly report of Biological shares 2021, the company's main income was 1.338 billion yuan, up 20.82% from the same period last year; the net profit was 419 million yuan, up 41.55% from the same period last year; and the non-net profit was 388 million yuan, up 33.45% from the same period last year. Among them, in the third quarter of 2021, the company's main income in a single quarter was 498 million yuan, up 3.02% from the same period last year; and the net profit in a single quarter was 161 million yuan, up 41.83% from the same period last year. The non-net profit in a single quarter was 136 million yuan, up 23.43% from the same period last year; the debt ratio was 14.91%, the investment income was 2.7554 million yuan, the financial expenses were-28.48 million yuan, and the gross profit margin was 62.11%.
A total of 12 agencies rated the stock in the last 90 days, including 10 buy ratings and 2 overweight ratings; the average institutional target price in the past 90 days was 23.63; in the past three months, the net financing outflow was 39.6218 million, and the financing balance decreased; the net inflow of securities was 4.9432 million, and the balance of securities lending increased. The Securities Star valuation analysis tool shows that the biological shares (600201) good company has a rating of 3.5star, a good price rating of 3.5star, and a comprehensive valuation rating of 3.5star.
The chairman of the company is Zhang Xianyu. Mr. Zhang Xianyu: born in 1954, Han nationality, Chinese nationality, master's degree, senior economist, from 2012 to May 2019, served as party committee secretary, chairman and president of our company. He has been the party committee secretary and chairman of the company since May 2019.
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If there are any questions in the article, please contact us.